<DOC>
	<DOCNO>NCT01339923</DOCNO>
	<brief_summary>The propose study aim assess safety immunogenicity rMenB+OMV NZ administer alone without routine infant vaccine healthy infant first year life accord different two three dose immunization schedule , suitable adopt various national program . This study also investigate antibody persistence post primary series administration subsequent booster dose rMenB+OMV NZ 11 month age . In addition , study assess safety immunogenicity two catch-up dos rMenB+OMV NZ administer healthy child 2 10 year age . This study also evaluate safety immunogenicity concomitant administration rMenB+OMV NZ meningococcal C conjugate vaccine ( MenC-CRM ) accord 3 , 5 12-month schedule .</brief_summary>
	<brief_title>A Phase 3B , Open Label , Multi-Center Study Evaluate Safety , Tolerability Immunogenicity Novartis Meningococcal B Recombinant Vaccine When Administered Alone Healthy Infants According Different Immunization Schedules Healthy Children Aged 2 10 Years</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy infant child accord follow age group : Healthy infant 2½ month age ( 71 79 day , inclusive ) , ( applicable group I ) Healthy infant 3½ month age ( 101 109 day , inclusive ) , ( applicable group II ) Healthy infants 6 month age ( applicable group III ) ( The age window define first day subject turn 6 month age day subject turn 7 month age ) . Healthy child 2 5 year age ( applicable group IVa ) ( The age window define first day subject turn 2 year age day subject turn 6 year age ) . Healthy child 6 10 year age ( applicable group IVb ) ( The age window define first day subject turn 6 year age day subject turn 11 year age ) . Healthy infant 3 month age ( 83104 day , inclusive ) , ( applicable Group V VI ) . 2 . For parent ( ) /legal guardian ( ) give write informed consent accord local regulation nature study explain ; 3 . Available visit schedule study ; 4 . Individuals good health determine outcome medical history , physical examination clinical judgment investigator . 1 . Individuals whose parent ( ) /legal guardian ( ) unwilling unable give write informed consent participate study ; 2 . Children 's parent legal guardian able comprehend follow require study procedure whole period study . 3 . History meningococcal B vaccine administration ; 4 . Previous ascertain suspected disease cause N. meningitidis ; 5 . Household contact and/or intimate exposure individual laboratory confirm N. meningitidis ; 6 . History severe allergic reaction previous vaccination hypersensitivity vaccine component 7 . Significant acute chronic infection within previous 7 day temperature 38° C within previous day receive study vaccine ; 8 . Antibiotics treatment within 6 day prior enrollment ; 9 . Individuals history allergy vaccine component . 10 . Any serious chronic progressive disease accord judgment investigator ( e.g. , neoplasm , diabetes mellitus Type I , cardiac disease , hepatic disease , neurological disease seizure , either associate fever part underlie neurological disorder syndrome , autoimmune disease , HIV infection AIDS , blood dyscrasia diathesis , sign cardiac renal failure severe malnutrition ) ; 11 . Known suspected impairment/alteration immune system , immunosuppressive therapy , use high dose systemic corticosteroid chronic use inhale highpotency corticosteroid within 14 day prior enrollment ( use low moderate dos inhale steroid exclusion ) ; 12 . Receipt blood , blood product and/or plasma derivative parenteral immunoglobulin preparation within 90 day prior enrollment . 13 . Receipt , intent immunize , vaccine ( ) within 7 day prior enrollment . 14 . Individuals participate clinical trial another investigational product 30 day prior first study visit intent participate another clinical study time conduct study . 15 . Family member household member research staff 16 . Individuals history illness , opinion investigator , might interfere result study pose additional risk subject due participation study . 17 . History meningococcal C vaccine administration ( Only applicable group V VI ) . 18 . History Pneumococcal vaccine administration ( Only applicable group V VI ) .</criteria>
	<gender>All</gender>
	<minimum_age>71 Days</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Meningococcal disease</keyword>
	<keyword>Vaccines</keyword>
	<keyword>intercalate administration</keyword>
</DOC>